Drug Trial Radar · NCT07951749
Evaluating Efficacy and Safety of Berotralstat in Preventing Angioedema Attacks in Subjects With Acquired Angioedema Due to C1 Inhibitor Deficiency (AAE)
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Nov 15, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- IRCCS Policlinico S. DonatoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary aim of the study is to explore the effectiveness of Berotralstat in preventing angioedema attacks in patients with Acquired Angioedema (AAE-C1-INH).
Conditions
- Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Interventions
BerotralstatDrug
Patients will receive capsules of oral Berotralstat for 24 weeks until the end of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Berotralstat EffectivenessTime frame: Up to 24 weeks.
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
A.O. "Ospedali Riuniti Villa Sofia-Cervello"
Palermo, Italy
Ospedale Luigi Sacco
Milan, Milan, Italy
IRCCS Policlinico San Donato
San Donato Milanese, Milan, Italy
Università degli Studi di Napoli Federico II
Naples, Naples, Italy
Azienda Ospedale-Università di Padova
Padova, Padua, Italy
Fondazione PTV Policlinico Tor Vergata
Roma, Rome, Italy
AO Ordine Mauriziano di Torino
Torino, Turin, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.